Dr. Mali's AAO 2022 Annual Meeting Hot Topics Post Meeting Reaction

<p>In this episode, I share my review of the hot topics from the AAO 2022 annual meeting and share my thoughts on the new data shared about drug trials and treatments.</p> <p><em>Brought to you by Alcon</em></p> <ul> <li>Welcome to another exciting episode of Eye Care insider <strong><em>:53</em></strong></li> <li>My review of the hot topics from the AAO 2022 annual meeting <strong><em>2:20</em></strong></li> <li>Hot Topic #1 – wet AMD treatments <strong><em>2:40</em></strong></li> <li>Hot Topic #2 – high-dose Eylea <strong><em>6:20</em></strong></li> <li>Hot Topic #3 – geographic atrophy treatments <strong><em>10:24</em></strong></li> <li>Thanks for listening <strong><em>16:04</em></strong></li> </ul> <p>We’d love to hear from you! Send your comments/questions to Dr. Mali at <a href= "mailto:eyecareinsider@healio.com">eyecareinsider@healio.com</a>. Follow us on Twitter <a href= "https://twitter.com/HRheuminations">@Healio_OSN</a>.</p> <p><strong>Disclosures:</strong> Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.</p>